Advertisement

Topics

E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. Pipeline Review, H1 2017

Summary

According to the recently published report 'E3 Ubiquitin Protein Ligase Mdm2 Pipeline Review, H1 2017'; E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. pipeline Target constitutes close to 27 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. E3 ubiquitinprotein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasomedependent ubiquitinindependent degradation of retinoblastoma RB1 protein. It inhibits DAXXmediated apoptosis by inducing its ubiquitination and degradation.

The report 'E3 Ubiquitin Protein Ligase Mdm2 Pipeline Review, H1 2017' outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 7 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Solid Tumor, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Breast Cancer, Lymphoma, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Glioblastoma Multiforme GBM, Osteosarcoma, Refractory Multiple Myeloma, Bone Cancer, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Colorectal Cancer, Dedifferentiated Liposarcoma, Diffuse Large BCell Lymphoma, Dry Atrophic Macular Degeneration, Follicular Lymphoma, Hematological Tumor, Leukemias, Liposarcoma, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Multiple Myeloma Kahler Disease, Peripheral TCell Lymphomas PTCL, Proliferative Vitreoretinopathy PVR, Relapsed Multiple Myeloma, Retinoblastoma, Soft Tissue Sarcoma, Uveal Melanoma and Well Differentiated Liposarcoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.
The report reviews E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. targeted therapeutics and enlists all their major and minor projects
The report assesses E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "E3 Ubiquitin Protein Ligase Mdm2 Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2. Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...